Biotricity to Discuss its 2022 Strategic Outlook and Product Pipeline, at Benzinga Healthcare Small Cap Conference on Sept. 30
Biotricity Inc. (NASDAQ:BTCY) announced its CEO, Waqaas Al Siddiq, will present at the Benzinga Healthcare Small Cap Conference on September 30, 2021, at 12:15 p.m. ET. The presentation will cover the company's strategic outlook for 2022, recent developments, and new products, including the Biokit bundle of wireless cardiac data devices. Biotricity aims to expand its market share and enhance shareholder value through its technology leadership and product pipeline. A replay of the presentation will be accessible on the corporate website for 30 days.
- CEO scheduled to present at a significant healthcare conference, enhancing visibility.
- Completion of financing aimed at supporting sales expansion while minimizing dilution.
- Launch of Biokit bundle integrates with Bioflux, expanding product offerings and market reach.
- None.
REDWOOD CITY, CA / ACCESSWIRE / September 28, 2021 / Biotricity Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that its Chief Executive Officer Waqaas Al Siddiq is scheduled to present at the virtual Benzinga Healthcare Small Cap Conference on Thursday, September 30, 2021 at 12:15 p.m. ET. Details are provided below.
Presentation Details:
What: Benzinga Healthcare Small Cap Conference
When: Thursday, September 30, 2021 - 12:15 p.m. EST
Event Website: https://www.benzinga.com/events/small-cap/healthcare/
Since August, the Company has completed a financing to support sales expansion while minimizing dilution and maximizing shareholder value, listed on the Nasdaq exchange, and unveiled its Biokit bundle of wireless cardiac data devices that integrate seamlessly with its Bioflux cardiac-diagnostic offering or operate independently for disease management.
Mr. Al Siddiq's presentation will feature the Company's outlook for 2022 as well as an insightful recap of recent events plus its new product pipeline, commercialization plans and how they all fit together in its strategy to increase its technological leadership, capture market share, and build shareholder value in the year ahead. The planned product portfolio, which complements the Bioflux cardiac-diagnostic offering, will expand the Company's total addressable market.
A replay of Biotricity's presentation will be archived on its corporate website and available for approximately 30 days following the event.
About Benzinga Small Cap Conference
The Benzinga Small Cap Conference bridges the gap between Small Cap companies, investors, and traders. Learn about small cap investing with clearly defined Educational Modules, take a look at a curated group of Small Cap investment opportunities, and connect with the healthcare Small Cap audience in an intimate, virtual setting.
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
###
Contacts
Donna Loughlin Michaels
LMGPR
408.393.5575
donna@lmgpr.com
Investor Relations
Biotricity Inc.
1-800-590-4155
investors@biotricity.com
SOURCE: Biotricity, Inc.
View source version on accesswire.com:
https://www.accesswire.com/665914/Biotricity-to-Discuss-its-2022-Strategic-Outlook-and-Product-Pipeline-at-Benzinga-Healthcare-Small-Cap-Conference-on-Sept-30
FAQ
What event is Biotricity's CEO presenting at?
What will the CEO discuss during the Benzinga Conference?
How is Biotricity working to enhance shareholder value?
What is the significance of the Biokit bundle?
